Table 3. Plasma lipoprotein concentrations before and after treatment.

Parameter	Ezetimibe				Simvastatin				Ezetimibe plus simvastatin
	Before therapy	After therapy	Mean percent change	P-value	Before therapy	After therapy	Mean percent change	P-value	Before therapy	After therapy	Mean percent change	P-value
Total cholesterol, mg/dl	180±28	159±23	−11.2±9.7	0.0002	194±34	145±24	−24.7±7.9	<0.0001	194±41	121±25	−36.9±8.1	<0.0001
LDL cholesterol, mg/dl	105±23	80±16	−22.1±10.2	<0.0001	113±30	67±22	−40.7±11.5	<0.0001	116±35	47±19	−59.6±9.7	<0.0001
HDL cholesterol, mg/dl	64±13	65±16	+1.7±11	0.35	65±18	65±16	+0.7±11.1	0.88	61±14	60±14	−1.5 ±8.5	0.23
Large HDL, mg/dl	22.1±7.6	21.2±8.1	−2.3±26.6		21.9±14.9	23.2±13.0	+15.9±32.0		20.2±8.9	21.4±8.1	+9.9±20.9
Intermediate HDL, mg/dl	31.7±5.1	32.7±6.0	+3.4±13.1		29.7±5.0	29.7±4.4	+1.2±13.6		28.4±4.3	27.7±5.6	−2.4±11.3
Small HDL, mg/dl	8.3±4.5	8.4±3.3	+13.6±48.2		13.9±4.7	12.0±4.3	−9.1±30.5		12.8±5.0	11.1±3.8	−8.8±26.1
Triglycerides, mg/dl	75 (59, 96)	73 (57, 90)	+27±79	0.57	87 (69, 126)	74 (53, 97)	−11.8±39.9	0.04	100 (67, 139)	82 (63, 123)	−8.9±29.7	0.03

Data are presented as mean ± SD and in the case of triglycerides as medians (interquartile range). Each group comprised n = 24 subjects (HDL subclass data in the ezetimibe group were available in only n = 22 subjects).